Quarterly report pursuant to Section 13 or 15(d)

Description of Business and Basis of Presentation - Additional Information (Detail)

v3.23.3
Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Basis Of Presentation [Line Items]            
Proceeds from the sale of common stock     $ 8,503 $ 5,635    
Net loss $ (4,589) $ (8,387) (15,306) (18,773)    
capital expenditures     1,100      
Gross proceeds from warrant exercises     800      
Working capital 8,000   8,000   $ 11,200  
Cash and cash equivalents 7,809   7,809   4,181  
Cash, cash equivalents, and restricted cash 7,809 $ 9,960 7,809 9,960 4,181 $ 30,175
Net cash and cash equivalents used in investing activities     (1,126) (3,256)    
Accounts receivable, net $ 4,388   4,388   $ 5,841  
Net cash used in operating activities     (11,808) $ (21,179)    
January 2023 Public Offering [Member]            
Basis Of Presentation [Line Items]            
Proceeds from the sale of common stock     8,500      
May 2023 Public Offering [Member]            
Basis Of Presentation [Line Items]            
Proceeds from the sale of common stock     3,700      
September 2023 Public Offering [Member]            
Basis Of Presentation [Line Items]            
Proceeds from the sale of common stock     $ 3,500      
BIOLASE stockholders [Member]            
Basis Of Presentation [Line Items]            
Reverse Stock Split     a reverse stock split of BIOLASE common stock, at a ratio between one-for-two (1:2) and one-for-one hundred (1:100). Immediately after the special meeting, BIOLASE's board of directors (the "Board") approved a one-for-one hundred (1:100) reverse stock split of the outstanding shares of BIOLASE common stock (the “2023 Reverse Stock Split”)